Explore listed projects, find initiatives that need your support and connect with the responsible researchers.
INO-4800 is a DNA vaccine candidate matched to the novel coronavirus SARS-CoV-2, which causes the COVID-19 disease in humans. Inovio's...
Inovio Pharmaceuticals Inc.; Beijing Advaccine Biotechnology.; US Department of Defense.; Ology Bioservices Inc.
Phase I
Nucleic acid-based
“We plan to leverage Heat Biologics’ proprietary vaccine platform to stimulate T-cell immune responses, which play a crucial role in...
University of Miami Miller School of Medicine
Pre-Clinical
Protein-based
Takeda is initiating the development of an anti-SARS-CoV-2 polyclonal hyperimmune globulin (H-IG) to treat high-risk individuals with...
Takeda Pharmaceutical Company
Pre-Clinical
Small molecule
Several research groups at Columbia University Irving Medical Center and the School of Engineering and Applied Sciences have projects...
Columbia University
Pre-Clinical
Chinese medical research institution in Beijing, Institute of Materia Medica, Chinese Academy of Medical Sciences, enters a strategic...
Institute Materia Medica, Chinese Academy of Medical Sciences
Pre-Clinical
A University of British Columbia investigator led an international team that has discovered an experimental drug that effectively blocks...
University of British Columbia; APEIRON Biologics; University of Toronto
Phase I
Other
CEPI, the Coalition for Epidemic Preparedness Innovations, today added an eighth COVID-19 vaccine candidate to its portfolio. CEPI will...
Institut Pasteur; Themis; University of Pittsburg
Pre-Clinical
Protein-based
Founded in 2010, Moderna uses messenger RNA, which carries genetic information from DNA to ribosomes to produce proteins. Moderna hijacks...
Moderna; National Institute of Allergy and Infectious Diseases
Phase I
Nucleic acid-based
Scientists at MIGAL Research Institute in Israel expect to start producing a Covid-19 vaccine in the next eight-ten weeks, based on their...
MIGAL Research Institute
Pre-Clinical
Whole-pathogen vaccines
We are rapidly developing human neutralizing monoclonal antibodies for SARS-CoV-2. We need funds or services in kind for manufacture and...
Vanderbilt Vaccine Center
Pre-Clinical
Protein-based
The World Health Organization has indicated that it will be approximately 18 months before a vaccine for COVID-19 is developed. Using our...
University of Iowa, Carver College of Medicine
Pre-Clinical
Other
We have developed a replication-deficient simian adenoviral vector vaccine expressing the SARS-CoV-2 surface Spike protein...
University of Oxford
Pre-Clinical
Subunit vaccines
An expert team of researchers and clinicians in microbiology, virology, pathology, molecular science, and immunology at the Icahn School...
Icahn School of Medicine at Mount Sinai
Pre-Clinical
Other